Project UpdateMay 6, 2026, 08:12 AM
Allarity Therapeutics Advances Stenoparib Phase 3 Manufacturing
AI Summary
Allarity Therapeutics announced that its active pharmaceutical ingredient (API) manufacturing campaign for stenoparib is progressing on schedule, with completion expected no later than the third quarter of 2026. This milestone is crucial for supporting the planned pivotal trial in advanced ovarian cancer and accelerating stenoparib toward FDA approval, especially given its Fast Track designation. The company also confirmed that all manufacturing-related payments have been completed, with no additional cash outlays anticipated.
Key Highlights
- Stenoparib API manufacturing campaign progressing on schedule.
- Completion of manufacturing expected no later than Q3 2026.
- Supports planned pivotal trial in advanced ovarian cancer.
- Accelerates stenoparib toward FDA approval, leveraging Fast Track designation.
- All manufacturing-related payments are complete, with no further cash outlays anticipated.
- Manufacturing conducted at a GMP-compliant CDMO site in Europe.
- Ongoing Phase 2 trial for advanced ovarian cancer continues patient enrollment.
- Separate Phase 2 trial for small cell lung cancer (SCLC) began enrolling patients in early 2026.
Price Impact
More from ALLR